VERTEX PHARMACEUTICALS INC / MA
For the period ended Jun 30, 2026. Filed Aug 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 4, 2026
VRTX$550.87+0.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(unaudited; in millions, except share and per share data)
| June 30, 2026 | December 31, 2025 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $6,143.5 | $5,084.8 |
| Marketable securities | 1,708.9 | 1,523.3 |
| Accounts receivable, net | 2,134.3 | 2,052.8 |
| Inventories | 1,765.1 | 1,686.8 |
| Prepaid expenses and other current assets | 791.9 | 853.3 |
| Total current assets | 12,543.7 | 11,201.0 |
| Property and equipment, net | 1,665.0 | 1,520.3 |
| Goodwill | 1,088.0 | 1,088.0 |
| Other intangible assets, net | 412.8 | 424.2 |
| Deferred tax assets | 3,010.9 | 2,897.9 |
| Operating lease assets | 1,662.9 | 1,562.7 |
| Long-term marketable securities | 5,789.1 | 5,712.3 |
| Other assets | 1,250.9 | 1,236.6 |
| Total assets | $27,423.3 | $25,643.0 |
| Liabilities and Shareholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $429.5 | $461.7 |
| Accrued expenses | 3,179.0 | 2,971.2 |
| Other current liabilities | 329.4 | 428.3 |
| Total current liabilities | 3,937.9 | 3,861.2 |
| Long-term operating lease liabilities | 1,977.6 | 1,846.5 |
| Other long-term liabilities | 1,259.9 | 1,269.5 |
| Total liabilities | 7,175.4 | 6,977.2 |
| Commitments and contingencies (Note L) | ||
| Shareholders’ equity: | ||
| Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued | — | — |
| Common stock, $0.01 par value; 500,000,000 shares authorized, 253,347,555 and 253,991,224 shares issued and outstanding, respectively | 2.5 | 2.5 |
| Additional paid-in capital | 4,505.7 | 5,119.2 |
| Accumulated other comprehensive income (loss) | 48.5 | (15.9) |
| Retained earnings | 15,691.2 | 13,560.0 |
| Total shareholders’ equity | 20,247.9 | 18,665.8 |
| Total liabilities and shareholders’ equity | $27,423.3 | $25,643.0 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.